geroprobПроблемы геронаукиProblems of Geroscience2949-47452949-4753АНО «ОСО ИТЕМ»10.37586/2949-4745-1-2023-7-14geroprob-5Research ArticleОбзорыReviewsСенолитические препараты: возможность применения в клинической практикеSenolytic drugs: implications for clinical practicehttps://orcid.org/0000-0002-3544-5347ИльющенкоА. К.IlyushchenkoA. K.

Ильющенко Анна Константиновна, врач-гериатр, младший научный сотрудник лаборатории биомаркеров старения

Ilyushchenko Anna K., MD, geriatrician, internist, Junior Researcher, Laboratory of Biomarkers of Aging

Ilyushchenko_ak@rgnkc.ruhttps://orcid.org/0000-0002-2028-3939МачехинаЛ. В.MatchekhinaL. V.

Мачехина Любовь Викторовна, канд. мед. наук, заведующая лабораторией биомаркеров старения

Machekhina Lubov V., MD, PhD, Head of Laboratory of Biomarkers of Aging

machehina_lv@rgnkc.ruhttps://orcid.org/0000-0002-4193-688XТкачеваО. Н.TkachevaO. N.

Ткачева Ольга Николаевна, член-корреспондент РАН, д-р мед. наук, профессор, директор

Tkacheva Olga N., MD, PhD, professor, corresponding member of the Russian Academy of Sciences. Director

tkacheva@rgnkc.ruhttps://orcid.org/0000-0003-0809-0787БалашоваА. В.BalashovaA. V.

Балашова Анастасия Владимировна, врач-эндокринолог, младший научный сотрудник лаборатории биомаркеров старения

Balashova Anastasiya V., MD, endocrinologist, Junior Researcher, Laboratory of Biomarkers of Aging

balashova_av@rgnkc.ruhttps://orcid.org/0009-0009-0858-2053МельницкаяА. А.MelnitskaiaA. A.

Мельницкая Александра Андреевна, врач-гериатр, младший научный сотрудник лаборатории биомаркеров старения

Melnitskaia Aleksandra A., MD, geriatrician, Junior Researcher, Laboratory of Biomarkers of Aging

melnickaya_aa@rgnkc.ruhttps://orcid.org/0000-0002-3920-7581ЧуровА. В.ChurovA. V.

Чуров Алексей Викторович, канд. биол. наук, директор института старения 

Churov Alexey V., PhD, Director, Institute for Aging Research

churov_av@rgnkc.ruhttps://orcid.org/0000-0002-3657-0676СтражескоИ. Д.StrazheskoI. D.

Стражеско Ирина Дмитриевна, д-р мед. наук, заместитель директора по трансляционной медицине

Strazhesko Irina D., MD, PhD, professor, Deputy Director for Translational Medicine

strazhesko_id@rgnkc.ruФГАОУ ВО РНИМУ им. Н.И. Пирогова Минздрава России, Российский геронтологический научно-клинический центр, Институт изучения старенияРоссияPirogov Russian National Research Medical University, Russian Gerontology Research and Clinical Centre, The Institute for Aging ResearchRussian Federation20231109202301714Copyright © Ильющенко А.К., Мачехина Л.В., Ткачева О.Н., Балашова А.В., Мельницкая А.А., Чуров А.В., Стражеско И.Д., 20232023Ильющенко А.К., Мачехина Л.В., Ткачева О.Н., Балашова А.В., Мельницкая А.А., Чуров А.В., Стражеско И.Д.Ilyushchenko A.K., Matchekhina L.V., Tkacheva O.N., Balashova A.V., Melnitskaia A.A., Churov A.V., Strazhesko I.D.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.geronauka.com/jour/article/view/5

Изучение механизмов старения — одна из важнейших целей современной науки. Благодаря фундаментальным исследованиям накоплен значительный объем данных о процессах, ассоциированных со снижением функциональной способности к регенерации, клеточной пролиферации и устойчивости к неблагоприятным факторам с возрастом. Целями обзора было изучить механизм действия препаратов с сенолитической активностью, определить основные мишени их воздействия на клеточном уровне, а также оценить перспективы их клинического применения. Актуальность данной темы подтверждается растущим числом клинических испытаний сенолитиков, многие из которых имеют неоднозначные результаты и требуют дальнейшего анализа и устранения выявленных сложностей и недостатков. Нами проведен обзор литературы на платформах Pubmed и Scopus за последние 10 лет с целью поиска информации о механизмах сенотерапии и возможности применения сенолитиков в клинической медицине. Основное внимание было сосредоточено на тех сенолитических препаратах, которые использовались в клинических исследованиях.

The aging mechanisms study is one of the most important aims in the field of geroscience and clinical medicine. There has been a wide range of fundamental research data accumulated on this matter. The processes associated with regeneration capability decrease, age-related decline of cell proliferation and resilience are highlighted in vitro studies, as well as on animal models, but their translation into clinical practice has not been carried out yet. Our aim was to study the most important mechanisms of aging and the ways of influencing on them with geroprotective technologies, such as senolytic medications. The relevance of this topic is confirmed by increasing number of launched clinical trials, but their results are often ambiguous and require further analysis and elimination of the identified difficulties and shortcomings. We have searched and analysed the literature over the past 10 years using Pubmed and Scopus, in order to find information about the main mechanisms of aging, and possible use of geroprotective medicatios in clinical practice.

геропротекторыклеточное старениесенолитикимеханизмы старенияSASPgeroprotectorscellular senescencesenolyticsaging mechanismsSASPФинансирование осуществлялось по программе «Приоритет-2030».ReferencesDobrokhleb VG. When Society Ages. Her Russ Acad Sci. 2021;91(5):587-592. DOI:10.1134/S1019331621050026Dobrokhleb VG. When Society Ages. Her Russ Acad Sci. 2021;91(5):587-592. DOI:10.1134/S1019331621050026Moskalev A, Chernyagina E, Kudryavtseva A, Shaposhnikov M. Geroprotectors: A Unified Concept and Screening Approaches. Aging Dis. 2017 May 2;8(3):354-363. DOI: 10.14336/AD.2016.1022. PMID: 28580190; PMCID: PMC5440114.Moskalev A, Chernyagina E, Kudryavtseva A, Shaposhnikov M. Geroprotectors: A Unified Concept and Screening Approaches. Aging Dis. 2017 May 2;8(3):354-363. DOI: 10.14336/AD.2016.1022. PMID: 28580190; PMCID: PMC5440114.Lagoumtzi SM, Chondrogianni N. Senolytics and senomorphics: Natural and synthetic therapeutics in the treatment of aging and chronic diseases. Free Radic Biol Med. 2021 Aug 1;171:169-190. doi: 10.1016/j.freeradbiomed.2021.05.003. Epub 2021 May 12. PMID: 33989756.Lagoumtzi SM, Chondrogianni N. Senolytics and senomorphics: Natural and synthetic therapeutics in the treatment of aging and chronic diseases. Free Radic Biol Med. 2021 Aug 1;171:169-190. doi: 10.1016/j.freeradbiomed.2021.05.003. Epub 2021 May 12. PMID: 33989756.Tchkonia T, Palmer AK, Kirkland JL. New Horizons: Novel Approaches to Enhance Healthspan Through Targeting Cellular Senescence and Related Aging Mechanisms. J Clin Endocrinol Metab. 2021 Mar 8;106(3):e1481-e1487. DOI: 10.1210/clinem/dgaa728Tchkonia T, Palmer AK, Kirkland JL. New Horizons: Novel Approaches to Enhance Healthspan Through Targeting Cellular Senescence and Related Aging Mechanisms. J Clin Endocrinol Metab. 2021 Mar 8;106(3):e1481-e1487. DOI: 10.1210/clinem/dgaa728Kirkland, James & Tchkonia, Tamara & Zhu, Yi & Niedernhofer, Laura & Robbins, Paul. (2017). The Clinical Potential of Senolytic Drugs. Journal of the American Geriatrics Society. 65. 10.1111/jgs.14969Kirkland, James & Tchkonia, Tamara & Zhu, Yi & Niedernhofer, Laura & Robbins, Paul. (2017). The Clinical Potential of Senolytic Drugs. Journal of the American Geriatrics Society. 65. 10.1111/jgs.14969Roger L, Tomas F, Gire V. Mechanisms and Regulation of Cellular Senescence. Int J Mol Sci. 2021;22(23):13173. Published 2021 Dec 6. DOI:10.3390/ijms222313173Roger L, Tomas F, Gire V. Mechanisms and Regulation of Cellular Senescence. Int J Mol Sci. 2021;22(23):13173. Published 2021 Dec 6. DOI:10.3390/ijms222313173Prieto LI, Baker DJ. Cellular Senescence and the Immune System in Cancer. Gerontology. 2019;65(5):505-512. DOI:10.1159/000500683Prieto LI, Baker DJ. Cellular Senescence and the Immune System in Cancer. Gerontology. 2019;65(5):505-512. DOI:10.1159/000500683Chandra A, Rajawat J. Skeletal Aging and Osteoporosis: Mechanisms and Therapeutics. Int J Mol Sci. 2021;22(7):3553. Published 2021 Mar 29. DOI:10.3390/ijms22073553Chandra A, Rajawat J. Skeletal Aging and Osteoporosis: Mechanisms and Therapeutics. Int J Mol Sci. 2021;22(7):3553. Published 2021 Mar 29. DOI:10.3390/ijms22073553Almeida MI, Silva AM, Vasconcelos DM, et al. miR-195 in human primary mesenchymal stromal/stem cells regulates proliferation, osteogenesis and paracrine effect on angiogenesis. Oncotarget. 2016;7(1):7-22. DOI:10.18632/oncotarget.6589Almeida MI, Silva AM, Vasconcelos DM, et al. miR-195 in human primary mesenchymal stromal/stem cells regulates proliferation, osteogenesis and paracrine effect on angiogenesis. Oncotarget. 2016;7(1):7-22. DOI:10.18632/oncotarget.6589Kudlova N, De Sanctis JB, Hajduch M. Cellular Senescence: Molecular Targets, Biomarkers, and Senolytic Drugs. Int J Mol Sci. 2022;23(8):4168. Published 2022 Apr 10. DOI:10.3390/ijms23084168Kudlova N, De Sanctis JB, Hajduch M. Cellular Senescence: Molecular Targets, Biomarkers, and Senolytic Drugs. Int J Mol Sci. 2022;23(8):4168. Published 2022 Apr 10. DOI:10.3390/ijms23084168Khosla S, Farr JN, Tchkonia T, Kirkland JL. The role of cellular senescence in ageing and endocrine disease. Nat Rev Endocrinol. 2020;16(5):263-275. DOI:10.1038/s41574-020-0335-yKhosla S, Farr JN, Tchkonia T, Kirkland JL. The role of cellular senescence in ageing and endocrine disease. Nat Rev Endocrinol. 2020;16(5):263-275. DOI:10.1038/s41574-020-0335-yAmaya-Montoya M, Pérez-Londoño A, Guatibonza-García V, Vargas-Villanueva A, Mendivil CO. Cellular Senescence as a Therapeutic Target for Age-Related Diseases: A Review. Adv Ther. 2020;37(4):1407-1424. DOI:10.1007/s12325-020-01287-0Amaya-Montoya M, Pérez-Londoño A, Guatibonza-García V, Vargas-Villanueva A, Mendivil CO. Cellular Senescence as a Therapeutic Target for Age-Related Diseases: A Review. Adv Ther. 2020;37(4):1407-1424. DOI:10.1007/s12325-020-01287-0Meijnikman A.S., van Olden C.C., Aydin O., Herrema H., Kaminska D., Lappa D., et al. Hyperinsulinemia is highly associated with markers of hepatocytic senescence in two independent cohorts. Diabetes. 2022;71(9):1929–1936.Meijnikman A.S., van Olden C.C., Aydin O., Herrema H., Kaminska D., Lappa D., et al. Hyperinsulinemia is highly associated with markers of hepatocytic senescence in two independent cohorts. Diabetes. 2022;71(9):1929–1936.Wang L., Wang B., Gasek N.S., Zhou Y., Cohn R.L., Martin D.E., et al. Targeting p21(Cip1) highly expressing cells in adipose tissue alleviates insulin resistance in obesity. Cell Metabolism. 2022;34(1):186.Wang L., Wang B., Gasek N.S., Zhou Y., Cohn R.L., Martin D.E., et al. Targeting p21(Cip1) highly expressing cells in adipose tissue alleviates insulin resistance in obesity. Cell Metabolism. 2022;34(1):186.Palmer AK, Tchkonia T, Kirkland JL. Targeting cellular senescence in metabolic disease. Mol Metab. 2022;66:101601. DOI:10.1016/j.molmet.2022.101601Palmer AK, Tchkonia T, Kirkland JL. Targeting cellular senescence in metabolic disease. Mol Metab. 2022;66:101601. DOI:10.1016/j.molmet.2022.101601Elsallabi O, Patruno A, Pesce M, Cataldi A, Carradori S, Gallorini M. Fisetin as a Senotherapeutic Agent: Biopharmaceutical Properties and Crosstalk between Cell Senescence and Neuroprotection. Molecules. 2022;27(3):738. Published 2022 Jan 23. DOI:10.3390/molecules27030738Elsallabi O, Patruno A, Pesce M, Cataldi A, Carradori S, Gallorini M. Fisetin as a Senotherapeutic Agent: Biopharmaceutical Properties and Crosstalk between Cell Senescence and Neuroprotection. Molecules. 2022;27(3):738. Published 2022 Jan 23. DOI:10.3390/molecules27030738Englund DA, Zhang X, Aversa Z, LeBrasseur NK. Skeletal muscle aging, cellular senescence, and senotherapeutics: Current knowledge and future directions. Mech Ageing Dev. 2021;200:111595. DOI:10.1016/j.mad.2021.111595Englund DA, Zhang X, Aversa Z, LeBrasseur NK. Skeletal muscle aging, cellular senescence, and senotherapeutics: Current knowledge and future directions. Mech Ageing Dev. 2021;200:111595. DOI:10.1016/j.mad.2021.111595Partridge, L., Fuentealba, M. & Kennedy, B.K. The quest to slow ageing through drug discovery. Nat Rev Drug Discov 19, 513– 532 (2020). DOI:10.1038/s41573-020-0067-7Partridge, L., Fuentealba, M. & Kennedy, B.K. The quest to slow ageing through drug discovery. Nat Rev Drug Discov 19, 513– 532 (2020). DOI:10.1038/s41573-020-0067-7Zhavoronkov A. Geroprotective and senoremediative strategies to reduce the comorbidity, infection rates, severity, and lethality in gerophilic and gerolavic infections. Aging (Albany NY). 2020;12(8):6492-6510. DOI:10.18632/aging.102988Zhavoronkov A. Geroprotective and senoremediative strategies to reduce the comorbidity, infection rates, severity, and lethality in gerophilic and gerolavic infections. Aging (Albany NY). 2020;12(8):6492-6510. DOI:10.18632/aging.102988Zhang L, Pitcher LE, Prahalad V, Niedernhofer LJ, Robbins PD. Targeting cellular senescence with senotherapeutics: senolytics and senomorphics [published online ahead of print, 2022 Jan 11]. FEBS J. 2022;10.1111/febs.16350. DOI:10.1111/febs.16350Zhang L, Pitcher LE, Prahalad V, Niedernhofer LJ, Robbins PD. Targeting cellular senescence with senotherapeutics: senolytics and senomorphics [published online ahead of print, 2022 Jan 11]. FEBS J. 2022;10.1111/febs.16350. DOI:10.1111/febs.16350Niedernhofer, L., Robbins, P. Senotherapeutics for healthy ageing. Nat Rev Drug Discov17, 377 (2018). DOI:10.1038/nrd.2018.44Niedernhofer, L., Robbins, P. Senotherapeutics for healthy ageing. Nat Rev Drug Discov17, 377 (2018). DOI:10.1038/nrd.2018.44Carreno G, Guiho R, Martinez-Barbera JP. Cell senescence in neuropathology: A focus on neurodegeneration and tumours. Neuropathol Appl Neurobiol. 2021;47(3):359-378. DOI:10.1111/nan.12689Carreno G, Guiho R, Martinez-Barbera JP. Cell senescence in neuropathology: A focus on neurodegeneration and tumours. Neuropathol Appl Neurobiol. 2021;47(3):359-378. DOI:10.1111/nan.12689Zhu Y, Tchkonia T, Pirtskhalava T, et al. The Achilles' heel of senescent cells: from transcriptome to senolytic drugs. Aging Cell. 2015;14(4):644-658. DOI:10.1111/acel.12344Zhu Y, Tchkonia T, Pirtskhalava T, et al. The Achilles' heel of senescent cells: from transcriptome to senolytic drugs. Aging Cell. 2015;14(4):644-658. DOI:10.1111/acel.12344Justice J. N. et al. Senolytics in idiopathic pulmonary fibrosis: results from a first-in-human, open-label, pilot study //EBioMedicine. — 2019. — Т. 40. — С. 554-563.Justice J. N. et al. Senolytics in idiopathic pulmonary fibrosis: results from a first-in-human, open-label, pilot study //EBioMedicine. — 2019. — Т. 40. — С. 554-563.Shao Z, Wang B, Shi Y, et al. Senolytic agent Quercetin ameliorates intervertebral disc degeneration via the Nrf2/NF-κB axis. Osteoarthritis Cartilage. 2021;29(3):413-422. DOI:10.1016/j.joca.2020.11.006Shao Z, Wang B, Shi Y, et al. Senolytic agent Quercetin ameliorates intervertebral disc degeneration via the Nrf2/NF-κB axis. Osteoarthritis Cartilage. 2021;29(3):413-422. DOI:10.1016/j.joca.2020.11.006Song S, Tchkonia T, Jiang J, Kirkland JL, Sun Y. Targeting Senescent Cells for a Healthier Aging: Challenges and Opportunities. Adv Sci (Weinh). 2020 Oct 19;7(23):2002611. DOI: 10.1002/advs.202002611. PMID: 33304768; PMCID: PMC7709980.Song S, Tchkonia T, Jiang J, Kirkland JL, Sun Y. Targeting Senescent Cells for a Healthier Aging: Challenges and Opportunities. Adv Sci (Weinh). 2020 Oct 19;7(23):2002611. DOI: 10.1002/advs.202002611. PMID: 33304768; PMCID: PMC7709980.Kovacovicova K, Skolnaja M, Heinmaa M, et al. Senolytic Cocktail Dasatinib+Quercetin (D+Q) Does Not Enhance the Efficacy of Senescence-Inducing Chemotherapy in Liver Cancer. Front Oncol. 2018;8:459. Published 2018 Oct 30. DOI:10.3389/fonc.2018.00459Kovacovicova K, Skolnaja M, Heinmaa M, et al. Senolytic Cocktail Dasatinib+Quercetin (D+Q) Does Not Enhance the Efficacy of Senescence-Inducing Chemotherapy in Liver Cancer. Front Oncol. 2018;8:459. Published 2018 Oct 30. DOI:10.3389/fonc.2018.00459Chang J, Wang Y, Shao L, et al. Clearance of senescent cells by ABT263 rejuvenates aged hematopoietic stem cells in mice. Nat Med. 2016;22(1):78-83. DOI:10.1038/nm.4010Chang J, Wang Y, Shao L, et al. Clearance of senescent cells by ABT263 rejuvenates aged hematopoietic stem cells in mice. Nat Med. 2016;22(1):78-83. DOI:10.1038/nm.4010Zhu Y, Tchkonia T, Fuhrmann-Stroissnigg H, et al. Identification of a novel senolytic agent, navitoclax, targeting the Bcl-2 family of antiapoptotic factors. Aging Cell. 2016;15(3):428-435. DOI:10.1111/acel.12445Zhu Y, Tchkonia T, Fuhrmann-Stroissnigg H, et al. Identification of a novel senolytic agent, navitoclax, targeting the Bcl-2 family of antiapoptotic factors. Aging Cell. 2016;15(3):428-435. DOI:10.1111/acel.12445Harrison CN, Garcia JS, Somervaille TCP, Foran JM, Verstovsek S, Jamieson C, Mesa R, Ritchie EK, Tantravahi SK, Vachhani P, O'Connell CL, Komrokji RS, Harb J, Hutti JE, Holes L, Masud AA, Nuthalapati S, Potluri J, Pemmaraju N. Addition of Navitoclax to Ongoing Ruxolitinib Therapy for Patients With Myelofibrosis With Progression or Suboptimal Response: Phase II Safety and Efficacy. J Clin Oncol. 2022 May 20;40(15):1671-1680. DOI: 10.1200/JCO.21.02188. PMID: 35180010; PMCID: PMC9113204.Harrison CN, Garcia JS, Somervaille TCP, Foran JM, Verstovsek S, Jamieson C, Mesa R, Ritchie EK, Tantravahi SK, Vachhani P, O'Connell CL, Komrokji RS, Harb J, Hutti JE, Holes L, Masud AA, Nuthalapati S, Potluri J, Pemmaraju N. Addition of Navitoclax to Ongoing Ruxolitinib Therapy for Patients With Myelofibrosis With Progression or Suboptimal Response: Phase II Safety and Efficacy. J Clin Oncol. 2022 May 20;40(15):1671-1680. DOI: 10.1200/JCO.21.02188. PMID: 35180010; PMCID: PMC9113204.Tse C., Shoemaker A.R., Adickes J., Anderson M.G., Chen J., Jin S. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res. 2008;68(9):3421–3428.Tse C., Shoemaker A.R., Adickes J., Anderson M.G., Chen J., Jin S. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res. 2008;68(9):3421–3428.Schoenwaelder SM, Jarman KE, Gardiner EE, et al. Bcl-xLinhibitory BH3 mimetics can induce a transient thrombocytopathy that undermines the hemostatic function of platelets. Blood. 2011;118(6):1663-1674. DOI:10.1182/blood-2011-04-347849Schoenwaelder SM, Jarman KE, Gardiner EE, et al. Bcl-xLinhibitory BH3 mimetics can induce a transient thrombocytopathy that undermines the hemostatic function of platelets. Blood. 2011;118(6):1663-1674. DOI:10.1182/blood-2011-04-347849National Center for Biotechnology Information. PubChem Compound Summary for CID 24978538, Navitoclax. https://pubchem.ncbi.nlm.nih.gov/compound/Navitoclax. Accessed May 23, 2023.National Center for Biotechnology Information. PubChem Compound Summary for CID 24978538, Navitoclax. https://pubchem.ncbi.nlm.nih.gov/compound/Navitoclax. Accessed May 23, 2023.Qi J., Liu Y., Yang P., et al. Heat shock protein 90 inhibition by 17-dimethylaminoethylamino-17-demethoxygeldanamycin protects blood-brain barrier integrity in cerebral ischemic stroke. American Journal of Translational Research. 2015;7(10):1826–1837Qi J., Liu Y., Yang P., et al. Heat shock protein 90 inhibition by 17-dimethylaminoethylamino-17-demethoxygeldanamycin protects blood-brain barrier integrity in cerebral ischemic stroke. American Journal of Translational Research. 2015;7(10):1826–1837Vannas C, Andersson L, Dolatabadi S, et al. Different HSP90 Inhibitors Exert Divergent Effect on Myxoid Liposarcoma In Vitro and In Vivo. Biomedicines. 2022;10(3):624. Published 2022 Mar 7. DOI:10.3390/biomedicines10030624Vannas C, Andersson L, Dolatabadi S, et al. Different HSP90 Inhibitors Exert Divergent Effect on Myxoid Liposarcoma In Vitro and In Vivo. Biomedicines. 2022;10(3):624. Published 2022 Mar 7. DOI:10.3390/biomedicines10030624Fuhrmann-Stroissnigg, H., Ling, Y.Y., Zhao, J. et al. Identification of HSP90 inhibitors as a novel class of senolytics. Nat Commun 8, 422 (2017). DOI:10.1038/s41467-017-00314-zFuhrmann-Stroissnigg, H., Ling, Y.Y., Zhao, J. et al. Identification of HSP90 inhibitors as a novel class of senolytics. Nat Commun 8, 422 (2017). DOI:10.1038/s41467-017-00314-zNational Center for Biotechnology Information. PubChem Compound Summary for CID 53316138, 17-Dmag. https://pubchem.ncbi.nlm.nih.gov/compound/17-Dmag. Accessed May 23, 2023.National Center for Biotechnology Information. PubChem Compound Summary for CID 53316138, 17-Dmag. https://pubchem.ncbi.nlm.nih.gov/compound/17-Dmag. Accessed May 23, 2023.Cherif H, Bisson DG, Mannarino M, Rabau O, Ouellet JA, Haglund L. Senotherapeutic drugs for human intervertebral disc degeneration and low back pain. Elife. 2020;9:e54693. Published 2020 Aug 21. DOI:10.7554/eLife.54693Cherif H, Bisson DG, Mannarino M, Rabau O, Ouellet JA, Haglund L. Senotherapeutic drugs for human intervertebral disc degeneration and low back pain. Elife. 2020;9:e54693. Published 2020 Aug 21. DOI:10.7554/eLife.54693Дятлова А. С., Дудков А., Линькова Н. С. и др. Молекулярные маркеры каспаза-зависимого митохондриального апоптоза: роль в развитии патологии и в процессах клеточного старения. // Успехи Современной Биологии 2018, №2, С. 126-137 [Dyatlova AS, Dudkov A, Lin’kova NS et al. Molekulyarnye markery kaspazazavisimogo mitokhondrial'nogo apoptoza: rol' v razvitii patologii i v protsessakh kletochnogo stareniya. Uspekhi Sovremennoy Biologii 2018;(2): 126-137 in RUSS] DOI:10.7868/s0042132418020023Дятлова А. С., Дудков А., Линькова Н. С. и др. Молекулярные маркеры каспаза-зависимого митохондриального апоптоза: роль в развитии патологии и в процессах клеточного старения. // Успехи Современной Биологии 2018, №2, С. 126-137 [Dyatlova AS, Dudkov A, Lin’kova NS et al. Molekulyarnye markery kaspazazavisimogo mitokhondrial'nogo apoptoza: rol' v razvitii patologii i v protsessakh kletochnogo stareniya. Uspekhi Sovremennoy Biologii 2018;(2): 126-137 in RUSS] DOI:10.7868/s0042132418020023Ray-Coquard I, Blay JY, Italiano A, et al. Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study. Lancet Oncol. 2012;13(11):1133-1140. DOI:10.1016/S1470-2045(12)70474-6Ray-Coquard I, Blay JY, Italiano A, et al. Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study. Lancet Oncol. 2012;13(11):1133-1140. DOI:10.1016/S1470-2045(12)70474-6National Center for Biotechnology Information. PubChem Compound Summary for CID 57406853. https://pubchem.ncbi.nlm.nih.gov/compound/rg7112. Accessed May 23, 2023.National Center for Biotechnology Information. PubChem Compound Summary for CID 57406853. https://pubchem.ncbi.nlm.nih.gov/compound/rg7112. Accessed May 23, 2023.Ishige K, Schubert D, Sagara Y. Flavonoids protect neuronal cells from oxidative stress by three distinct mechanisms. Free Radic Biol Med. 2001;30(4):433-446. DOI:10.1016/s0891-5849(00)00498-6Ishige K, Schubert D, Sagara Y. Flavonoids protect neuronal cells from oxidative stress by three distinct mechanisms. Free Radic Biol Med. 2001;30(4):433-446. DOI:10.1016/s0891-5849(00)00498-6Zhu Y, Doornebal EJ, Pirtskhalava T, et al. New agents that target senescent cells: the flavone, fisetin, and the BCL-XL inhibitors, A1331852 and A1155463. Aging (Albany NY). 2017;9(3):955-963. DOI:10.18632/aging.101202Zhu Y, Doornebal EJ, Pirtskhalava T, et al. New agents that target senescent cells: the flavone, fisetin, and the BCL-XL inhibitors, A1331852 and A1155463. Aging (Albany NY). 2017;9(3):955-963. DOI:10.18632/aging.101202Demaria M, Ohtani N, Youssef SA, et al. An essential role for senescent cells in optimal wound healing through secretion of PDGFAA. Dev Cell. 2014;31(6):722-733. DOI:10.1016/j.devcel.2014.11.012Demaria M, Ohtani N, Youssef SA, et al. An essential role for senescent cells in optimal wound healing through secretion of PDGFAA. Dev Cell. 2014;31(6):722-733. DOI:10.1016/j.devcel.2014.11.012COVID-FISETIN: Pilot in SARS-CoV-2 of Fisetin to Alleviate Dysfunction and Inflammation. [Электронный ресурс]. [дата обраще- ния 09.04.2023]. URL:https://clinicaltrials.gov/ct2/show/NCT04476953COVID-FISETIN: Pilot in SARS-CoV-2 of Fisetin to Alleviate Dysfunction and Inflammation. [Электронный ресурс]. [дата обраще- ния 09.04.2023]. URL:https://clinicaltrials.gov/ct2/show/NCT04476953National Center for Biotechnology Information. PubChem Compound Summary for CID 5281614, Fisetin. https://pubchem.ncbi.nlm.nih.gov/compound/Fisetin. Accessed May 23, 2023.National Center for Biotechnology Information. PubChem Compound Summary for CID 5281614, Fisetin. https://pubchem.ncbi.nlm.nih.gov/compound/Fisetin. Accessed May 23, 2023.Valieva Y, Ivanova E, Fayzullin A, Kurkov A, Igrunkova A. Senescence-Associated β-Galactosidase Detection in Pathology. Diagnostics (Basel). 2022;12(10):2309. Published 2022 Sep 25. DOI:10.3390/diagnostics12102309Valieva Y, Ivanova E, Fayzullin A, Kurkov A, Igrunkova A. Senescence-Associated β-Galactosidase Detection in Pathology. Diagnostics (Basel). 2022;12(10):2309. Published 2022 Sep 25. DOI:10.3390/diagnostics12102309Shivarathri R, Jenull S, Stoiber A, et al. The Two-Component Response Regulator Ssk1 and the Mitogen-Activated Protein Kinase Hog1 Control Antifungal Drug Resistance and Cell Wall Architecture of Candida auris. mSphere. 2020;5(5):e00973-20. Published 2020 Oct 14. DOI:10.1128/mSphere.00973-20Shivarathri R, Jenull S, Stoiber A, et al. The Two-Component Response Regulator Ssk1 and the Mitogen-Activated Protein Kinase Hog1 Control Antifungal Drug Resistance and Cell Wall Architecture of Candida auris. mSphere. 2020;5(5):e00973-20. Published 2020 Oct 14. DOI:10.1128/mSphere.00973-20Cai, Y., Zhou, H., Zhu, Y. et al. Elimination of senescent cells by β-galactosidase-targeted prodrug attenuates inflammation and restores physical function in aged mice. Cell Res30, 574–589 (2020). DOI:10.1038/s41422-020-0314-9Cai, Y., Zhou, H., Zhu, Y. et al. Elimination of senescent cells by β-galactosidase-targeted prodrug attenuates inflammation and restores physical function in aged mice. Cell Res30, 574–589 (2020). DOI:10.1038/s41422-020-0314-9Jiang KX, Liu QQ, Bai N, Zhu MC, Zhang KQ, Yang JK. AoSsk1, a Response Regulator Required for Mycelial Growth and Development, Stress Responses, Trap Formation, and the Secondary Metabolism in Arthrobotrys oligospora. J Fungi (Basel). 2022;8(3):260. Published 2022 Mar 3. DOI:10.3390/jof8030260Jiang KX, Liu QQ, Bai N, Zhu MC, Zhang KQ, Yang JK. AoSsk1, a Response Regulator Required for Mycelial Growth and Development, Stress Responses, Trap Formation, and the Secondary Metabolism in Arthrobotrys oligospora. J Fungi (Basel). 2022;8(3):260. Published 2022 Mar 3. DOI:10.3390/jof8030260National Center for Biotechnology Information. PubChem Compound Summary for CID 162642741. https://pubchem.ncbi.nlm.nih.gov/compound/162642741. Accessed May 24, 2023.National Center for Biotechnology Information. PubChem Compound Summary for CID 162642741. https://pubchem.ncbi.nlm.nih.gov/compound/162642741. Accessed May 24, 2023.

The authors declare that there are no conflicts of interest present.